Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00542009 · ClinicalTrials.gov registry record · Phase 2

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

A Phase 2 study of Weight Management and Treatment Of Obesity, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
252
Enrollment target
20
Study locations

NCT00542009 is a Phase 2 study of Weight Management and Treatment Of Obesity that has completed, run by Pfizer. The registered enrollment target is 252 participants, below the 837-participant average among 8 other Weight Management trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00542009, a Phase 2 study of Weight Management and Treatment Of Obesity, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
252 participants
Enrollment target
20
Study locations

Study Summary

Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes

Conditions Studied

Weight Management Treatment Of Obesity

Interventions

  • DRUG Placebo
  • DRUG CE-326,597 100 mg QD
  • DRUG CE-326,597 50 mg QD
  • DRUG CE-326,597 25 mg QD
  • DRUG CE-326,597 5mg QD

Study Locations (20)

California

  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - National City
  • Pfizer Investigational Site - San Diego

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Ocala
  • Pfizer Investigational Site - West Palm Beach

Georgia

  • Pfizer Investigational Site - Atlanta
  • Pfizer Investigational Site - Conyers

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Chicago

Minnesota

  • Pfizer Investigational Site - Chaska
  • Pfizer Investigational Site - Minneapolis

Nevada

  • Pfizer Investigational Site - Henderson
  • Pfizer Investigational Site - Las Vegas

Arizona

  • Pfizer Investigational Site - Phoenix

Hawaii

  • Pfizer Investigational Site - Honolulu

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2007-12
Est. Completion 2008-11
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00542009

The ClinicalTrials.gov registry entry for NCT00542009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 837-participant average among 8 other Weight Management trials with a reported enrollment target (70% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Weight Management appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT00542009 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00542009 about?

NCT00542009 is a clinical study titled "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight". Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes

What is the current status of trial NCT00542009?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2007-12. Estimated completion is 2008-11.

What conditions does trial NCT00542009 study?

This clinical trial studies the following conditions: Weight Management, Treatment Of Obesity.

What interventions are being tested in trial NCT00542009?

The interventions under investigation include: Placebo (DRUG), CE-326,597 100 mg QD (DRUG), CE-326,597 50 mg QD (DRUG), CE-326,597 25 mg QD (DRUG), CE-326,597 5mg QD (DRUG).

Who is sponsoring clinical trial NCT00542009?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00542009 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Weight Management

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Weight Management

All registered trials for this condition

Treatment Of Obesity

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.